Charles Schwab Investment Management Inc. Sells 5,595 Shares of BioLife Solutions, Inc. $BLFS

Charles Schwab Investment Management Inc. lessened its position in shares of BioLife Solutions, Inc. (NASDAQ:BLFS) by 1.6% in the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 340,826 shares of the medical equipment provider’s stock after selling 5,595 shares during the period. Charles Schwab Investment Management Inc. owned approximately 0.72% of BioLife Solutions worth $7,784,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors have also added to or reduced their stakes in BLFS. Point72 Asia Singapore Pte. Ltd. acquired a new position in BioLife Solutions during the 4th quarter worth approximately $31,000. US Bancorp DE increased its position in BioLife Solutions by 243.7% during the 1st quarter. US Bancorp DE now owns 2,155 shares of the medical equipment provider’s stock worth $49,000 after purchasing an additional 1,528 shares in the last quarter. GAMMA Investing LLC increased its position in BioLife Solutions by 18.6% during the 1st quarter. GAMMA Investing LLC now owns 4,223 shares of the medical equipment provider’s stock worth $96,000 after purchasing an additional 663 shares in the last quarter. Avantax Advisory Services Inc. increased its position in BioLife Solutions by 16.0% during the 1st quarter. Avantax Advisory Services Inc. now owns 9,077 shares of the medical equipment provider’s stock worth $207,000 after purchasing an additional 1,250 shares in the last quarter. Finally, Graham Capital Management L.P. acquired a new position in BioLife Solutions during the 4th quarter worth approximately $254,000. 93.24% of the stock is currently owned by institutional investors and hedge funds.

BioLife Solutions Stock Performance

NASDAQ:BLFS opened at $25.65 on Tuesday. The firm’s fifty day moving average is $22.39 and its 200-day moving average is $23.37. BioLife Solutions, Inc. has a 52 week low of $19.10 and a 52 week high of $29.55. The firm has a market cap of $1.23 billion, a P/E ratio of -213.73 and a beta of 1.76.

BioLife Solutions (NASDAQ:BLFS) last posted its quarterly earnings data on Thursday, August 7th. The medical equipment provider reported ($0.33) EPS for the quarter, missing analysts’ consensus estimates of ($0.02) by ($0.31). BioLife Solutions had a negative net margin of 5.39% and a positive return on equity of 0.16%. The firm had revenue of $25.42 million during the quarter, compared to the consensus estimate of $23.71 million. BioLife Solutions has set its FY 2025 guidance at EPS. As a group, sell-side analysts anticipate that BioLife Solutions, Inc. will post -0.3 earnings per share for the current year.

Insider Activity at BioLife Solutions

In other news, major shareholder Casdin Partners Master Fund, L sold 500,000 shares of the company’s stock in a transaction on Friday, August 15th. The shares were sold at an average price of $24.40, for a total value of $12,200,000.00. Following the sale, the insider directly owned 6,707,165 shares of the company’s stock, valued at approximately $163,654,826. This represents a 6.94% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Over the last 90 days, insiders have sold 2,008,831 shares of company stock valued at $47,499,658. Corporate insiders own 2.20% of the company’s stock.

Analysts Set New Price Targets

BLFS has been the subject of a number of research analyst reports. Stephens initiated coverage on shares of BioLife Solutions in a research report on Tuesday, July 22nd. They set an “overweight” rating and a $30.00 price objective for the company. Wall Street Zen cut shares of BioLife Solutions from a “hold” rating to a “sell” rating in a research report on Wednesday, May 21st. HC Wainwright restated a “buy” rating and issued a $32.00 price target (up from $30.00) on shares of BioLife Solutions in a research report on Friday, August 8th. Finally, Zacks Research upgraded shares of BioLife Solutions to a “strong-buy” rating in a research report on Monday, August 11th. One research analyst has rated the stock with a Strong Buy rating and seven have assigned a Buy rating to the company. Based on data from MarketBeat, the stock has an average rating of “Buy” and an average target price of $31.29.

BioLife Solutions Profile

BioLife Solutions, Inc develops, manufactures, and markets bioproduction tools and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company’s products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies.